

MEMBER OF THE ESC JOURNAL FAMILY

European Heart Journal

Journal of the European Society of Cardiology

ESC Congress 2015 29 August - 2 September London, United Kingdom

Special Edition

Editor-in-Chief: Thomas F. Lüscher Deputy Editors: Jeroen J. Bax Bernard J. Gersh Gerhard Hindricks Ulf Landmesser Frank Ruschitzka William Wijns





www.eurheartj.org

Conclusion: Our pilot study shows a superior correlation between RAV and RAP measured by right heart catheterization compared with IVC size and respiratory variation. We are currently conducting a study on a larger cohort of patients in order to validate these results.

P5944 | BEDSIDE

Detection of clinically stable myocardial ischaemic segments confirmed by invasive fractional flow reserve using resting 2D speckle tracking echocardiographic multi-layer strain: 13 months follow up


T. Nishi¹, N. Funabashi², K. Ozawa², M. Takahara², H. Takaoka², Y. Fujimoto², Y. Kobayashi². ¹*Chiba University Graduate School of Medicine, Department of cardiology, Chiba, Japan;* ²*Chiba University Graduate School of Medicine, Department of Cardiovascular Medicine, Chiba, Japan*

Background: Endocardial layer of left ventricular (LV) wall is more vulnerable to ischemia than epicardial layer. Multi-layer speckle tracking transthoracic echocardiography (TTE) yields quantitative strain measurements of LV endocardial and epicardial layers contributing to early detection of ischemic myocardium without drug or exercise loading.

Purpose: To detect LV myocardial stable ischemic segments using non-invasive multi-layer TTE and confirm actual prognosis.

Methods: This was a retrospective analysis of 39 stable patients (32 males; $65.8\pm11.9 \text{ yr}$) with 46 coronary arteries with $\geq 50\%$ stenosis confirmed by invasive coronary angiography undergoing invasive fractional flow reserve (FFR) measurement and TTE (Vivid E9) within 36 days without clinical incident. On TTE, regional longitudinal strain (LS) in whole, endocardial, and epicardial layer supplied by stenotic coronary vessels was calculated. Patients were followed for a median of 13 months. Adverse events included death, myocardial infarction (MI) and urgent revascularization.

Results: Of 46 vessels, FFR was <0.75, \geq 0.75, \leq 0.80 and >0.80 in 17, 29, 27 and 19 vessels, respectively. Whole- layer and endocardial LS were significantly greater in LV segments with FFR<0.75 than when FFR \geq 0.75 (both P<0.05). No significant differences of epicardial LS between LV segments with FFR<0.75 and \geq 0.75 and of all LS between LV segments with FFR<0.80 or FFR>0.80 were observed. Endocardial LS showed a slightly negative correlation with FFR (R=-0.299, P=0.044). Adverse events occurred in one patient (MI) whose FFR was 0.56.



Conclusion: In stable subjects with coronary arteries with \geq 50% stenosis, regional whole-layer and endocardial, but not epicardial LS distinguished LV segments with FFR<0.75 from those with \geq 0.75 using 2D TTE.

ION CHANNEL AND CARDIOMYOPATHY: THE NEGLECTED LINK

P5945 | BENCH

A missense mutation in the transcription factor TBX20 gene causes long QT syndrome

A. Barana¹, M. Matamoros¹, I. Amoros¹, M. Perez-Hernandez¹, M. Nunez¹,
D. Filgueiras-Rama², R. Caballero¹, J.L. Lopez-Sendon², J. Tamargo¹,
E. Delpon¹. ¹Complutense University of Madrid, Madrid, Spain; ²University Hospital La Paz, Cardiology, Madrid, Spain

Introduction: We describe a heterozygous missense mutation in the gene encoding the T-box transcription factor TBX20 found in a proband diagnosed with long QT syndrome. The proband is a 45 aged male who has been asymptomatic so far. Clinical evaluation of the family led to the identification of two sisters who died suddenly and two other diagnosed with long QT syndrome who wear implantable defibrillators. His mother was successfully resuscitated from sudden death and recently died from leukaemia. Next Generation Sequencing of samples from the proband and affected relatives revealed a missense mutation located in the transactivation domain of TBX20 (p.R311C), that was confirmed by Sanger. Screening for mutations in all described long QT syndrome genes was negative. **Purpose:** This work aimed to determine the functional consequences of this mutation and the mechanism by which it can lead to QT interval prolongation.

Methods: WT and mutated TBX20 tagged with GFP were expressed in HL-1 cells and endogenous currents were recorded at room temperature using the wholecell patch-clamp.

Results: Expression of WT or p.R311C TBX20 in HL-1 cells did not significantly modified peak or late sodium current (INa) compared to that recorded in control conditions (–45.9±17.0 pA/pF and –2.1±0.5 pA/pF, respectively). Identical results were obtained when L-type calcium (ICa,L) and inward rectifier (IK1) currents were analyzed. Next, we determined putative effects of the mutation on the IKr measured as the dofetilide-sensitive current. Expression of WT TBX20 significantly increased IKr tail current density (from 2.5±0.3 to 3.6±0.3 pA/pF at +60 mV, P<0.05). Interestingly, p.R311C TBX20 markedly reduced tail current density to 2.0±0.2 pA/pF (P<0.05). However, neither WT nor p.R311C TBX20 modified the density of the dofetilide-insensitive current (IKs). A mathematical model of human ventricular action potential demonstrated that p.R311C TBX20 prolonged action potential duration (APD) measured at 50 and 90% of repolarization by 26.7 and 28.3%, respectively. Analysis of the promoter sequence of the ion channels responsible for IKr (KCNH2) revealed a conserved TBX20 binding motif near the transcription start site. Luciferase reporter assays demonstrated that WT TBX20 significantly increased KCNH2 promoter activity, whereas p.R311C TBX20 mutation completely abrogated this effect.

Conclusions: The present results demonstrate that a missense mutation in TBX20 lead to APD lengthening by means of a reduction in IKr density and allow the identification of TBX20 as a novel gene associated with long QT syndrome.

P5946 | BENCH

VEGF-B induces a unique electrophysiological phenotype in mouse heart

J. Huusko, N. Naumenko, M. Merentie, E. Gurzeler, A. Laine, S. Yla-Herttuala, P. Tavi. *A.I. Virtanen Institute for Molecular Sciences at the University of Eastern Finland, Kuopio, Finland*

Background: Cardiac effects of vascular growth factors (VEGFs) have mainly been studied in the context of angiogenic gene therapy to enhance perfusion of the heart. However, the role of VEGFs in the heart seems not to be restricted only to angiogenesis. Recently, VEGF-B has been implicated in myocardial metabolism and is involved in and modulates heart's response to pathological stress. However, the effects of VEGF-B on myocardial function are not known.

Purpose: The purpose of this study was to assess the effects of VEGF-B on the contractile and electrophysiological properties of the mouse heart.

Methods: Echocardiographic and ECG monitoring of cardiac-specific VEGF-B overexpressing mice (TG) and their litter mate controls (WT) were done with Vevo2100 small animal ultrasound. The effect of beta-adrenoceptor agonist, dobutamin, on ECG was studied by i.p. injections. Conventional whole-cell voltage- and current-clamp was used for currents and action potential recordings (Axopatch 200B). Gene expressions were measured with qPCR and Western blot.

Results: In vivo contractile function or the morphology of TG hearts did not differ from WT hearts. However, ECG measurements showed a decrease in the R and S amplitudes as well as in PQ time and an increase in the QRS time in TG mice compared to the WT mice. Isolated TG cardiomyocytes had increased duration (APD90; 55.8%, p=0.005) and rise time (47.1%, p=0.00001) of the action potentials. These were accompanied by a decrease in the density of the sodium current (20.8% at -40mV, p=0.0005) and in the transient outward K+current (57% at 50mV, p=0.0004), while ultra-rapid (34.8%, p=0.04 at 50mV) and steady state K+-currents (149%, p=0.01, at 50 mV) were both increased. In line with this, expressions of ion-channel subunits were changed; SCN5A, a gene of voltage-gated sodium channel (type V, alpha) was downregulated by 32.2% (p=0.02), Kcnip2 gene (Kv channel-interacting protein 2) downregulated by 42% (p=0.03) and Kcna5 gene (potassium voltage-gated channel) was upregulated by 36% (p=0.03). These electrophysiological changes predisposed TG animals to catecholamine-induced arrhythmias: upon dobutamine injection 60% TG vs. 10% WT mice developed severe arrhythmias.

Conclusion: Cardiac VEGF-B overexpression results in remodelling of cardiomyocyte ion currents, resulting in changes of the action potential waveform and unique ECG changes resembling those seen in long-QT-syndromes. Altogether, cardiac overexpression of VEGF-B induces a unique electrophysiological phenotype predisposing animals to arrhythmias.

P5947 | BENCH

Heart failure is associated with distinct remodelling of atrial repolarising K2P K+ channels in patients with atrial fibrillation

C. Schmidt¹, F. Wiedmann¹, X.B. Zhou², N. Voigt³, S. Kallenberger⁴, M. Karck⁵, M. Borggrefe², D. Dobrev³, D. Thomas¹. ¹University Hospital of Heidelberg, Cardiology, Heidelberg, Germany; ²University Medical Centre of Mannheim, Mannheim, Germany; ³Institute of Pharmacology, Essen, Germany; ⁴German Cancer Research Center, Department for Bioinformatics and Functional Genomics, Heidelberg, Germany; ⁵University Hospital of Heidelberg, Department of Cardiac Surgery, Heidelberg, Germany

Introduction - The prevalence of atrial fibrillation (AF) increases with advanced stages of heart failure (HF). Molecular effects of ventricular dysfunction on atrial arrhythmogenesis remain to be elucidated. We hypothesized that repolarising two-pore-domain (K2P) K+ channels are differentially regulated and contribute to proarrhythmic substrate in AF patients with concomitant HF.

Purpose: The purpose of this study was to assess K2P channel remodelling in patients with AF complicated by varying HF stages.

Methods: Right atrial tissue was acquired from a cohort of 135 patients with

ESC Congress 2015, London, United Kingdom

29 August – 2 September 2015



European Heart Journal

www.eurheartj.org

EDITOR-IN-CHIEF

Thomas F. Lüscher

DEPUTY EDITORS

Jeroen J. Bax Bernard J. Gersh Gerhard Hindricks

CONSULTING EDITORS

Anthony N. DeMaria Joe Loscalzo Frans Van de Werf

INTERNATIONAL ASSOCIATE EDITORS

Colin Baigent Helmut Baumgartner Paolo Camici David Celermajer (AU) Francesco Cosentino Filippo Crea John E. Deanfield Stephanie Dimmeler Volkmar Falk Gerasimos Filippatos Keith A.A. Fox Runlin Gao (Asia) John Gorcsan III (US) John J.P. Kastelein Patrizio Lancellotti John J.V. McMurray Christian Mueller Barbara Mulder Thomas Münzel B. Nallamothu (US) Stefan Neubauer Udo P. Sechtem Hiroaki Shimokawa (JP) Jagmeet P. Singh (US) Karen Sliwa (ZA) Karl Swedberg Stefano Taddei Thomas Thum Alec Vahanian Salim Yusuf (CA)

Ulf Landmesser

William Wijns

Frank Ruschitzka

LOCAL ASSOCIATE EDITORS

Ronald Binder Corinna Brunckhorst Giovanni G. Camici Firat Duru Frank Enseleit Urs Eriksson Andreas Flammer Oliver Gämperli Nils Kucher Willibald Maier Robert Manka Christian Matter Fabian Nietlispach Christian Schmied Jan Steffel Felix C. Tanner Christian Templin

STATISTICS EDITOR

Rickey Carter

SENIOR CONSULTING EDITORS

Stefan Agewall John Camm Diederick E. Grobbee Tiny Jaarsma Gerald Maurer Marco Metra Patrick W. Serruys Karin Sipido Adam Timmis Christian J.M. Vrints

ETHICS REVIEW BOARD

Maarten L. Simoons Kim M. Fox Christian Hamm

EDITORIAL OFFICE

European Heart Journal The Zurich Heart House Moussonstrasse 4 CH-8091 Zurich Switzerland Phone: +41 (0)44 634 5537/38 Fax: +41 (0)44 634 5530 Email: Eurheartj@usz.ch Homepage: www.eurheartj.org

MANAGING EDITORS

Sam Rogers Susanne B. Dedecke Amelia Meier-Batschelet Andros Tofield (CardioPulse and People's Corner)

CLINICAL REVIEW EDITOR

Freek W.A. Verheugt

INTERNATIONAL EDITORIAL BOARD

William T. Abraham (US) Stephan Achenbach (DE) . Takashi ∆kasaka (JP) Fernando Alfonso (ES)* Joseph S. Alpert (US) Giuseppe Ambrosio (IT) Felicita Andreotti (IT) Stefan Anker (DE) Elliott M. Antman (US) David Antoniucci (IT) Eliosa Arbustini (IT) Paul W. Armstrong (CA) Dan Atar (NO) Johann Auer (AT)* Álvaro Avezum (BR) Luigi P. Badano (IT) Sang Hong Baek (KP) Emanuele Barbato (BE) Thomas Bartel (AT) Joshua Barzilay (US)* Jean-Pierre Bassand (FR) Jean-Merre bassand (FK) Eric Bates (US) Hans-Jurg Beer (CH) Emelia Benjamin (US) Michel E. Bertrand (FR) Deepak L. Bhatt (US) Luigi M. Biasucci (IT) Giuseppe G.L. Biondi-Zoccai (IT) Cheitenb Red (JE)* Christoph Bode (DE)* Eric Boersma (NL) Lucas V.A. Boersma (NL) Giovanni Boffa (IT)* Robert O. Bonow (US) Giuseppe Boriani (IT) Jeffrey Borer (US) Jertrey Borer (US) Michael Böhm (DE) Barry A. Borlaug (US) Somjot S. Brar (US) Eugene Braunwald (US) Günter Breithardt (DE) Ole Breithardt (DE) Michele Brignole (IT) Pedro Brugada (BE) Nico Bruining (NL) Raffaele Bugiardini (IT) Hans-Peter Brunner-La Rocca (NL) Robert M. Califf (US) Francois Cambien (FR) Christopher Paul Cannon (US) Davide Capodanno (IT)* Edoardo Casiglia (IT)* Filip P. Casselman (BE) Bernard R. Chaitman (US) Marietta Charakida (UK) Evgeny L. Chazov (RU) John G.F. Cleland (GB) David J. Cohen (US) Antonio Colombo (IT) C. Richard Conti (US) Leslie Cooper (US) Maria R. Costanzo (US)

Mark A. Creager (US) Harry Crijns (NL) Nicolas Danchin (FR) Isabel Deisenhofer (DE) Victoria Delgado (NL) Kenneth Dickstein (N) Raffaele De Caterina (IT) Bart De Geest (BE)* Pascal de Groote (FR) Edo D. de Muinck (SE) Carlo Di Mario (GB) Raimund Erbel (DE) Paul Erne (CH)* Cetin Erol (TU) Francisco Fernández-Avilés (ES) Roberto Ferrari (IT) Andrea Frustaci (IT) Valentin Fuster (US) Nazzareno Galie (IT Xavier Garcia-Moll (ES) Anthony H. Gershlick (GB) Lorenzo Ghiadoni (IT) Anselm Kai Gitt (DE) Samuel Z. Goldhaber (US) Paolo Golino (IT) Lino Gonçalves (PT) Tommaso Gori (DE)* Christopher Granger (US) Daniel Gras (F) Steven M. Haffner (US) Michel Haïssaguerre (FR) Christian Hamm (DE) Robert Harrington (US) Gerd Hasenfuss (DE) Adrian F. Hernandez (US) Gerd Heusch (DE) Judith S. Hochman (US) David R. Holmes, Jr (US) John Horowitz (AU) Kurt Huber (AT)* Sabino Illiceto (IT) Bernard lung (FR) Allan S. Jaffe (US) Stefan James (SE) Stefan Janssens (BE) James L. Januzzi (US) Gabriela Kania (CH) Juan-Carlos Kaski (UK) Adnan Kastrati (DE) Adnan Kastrati (DE) Hugo Katus (DE) Philipp A. Kaufmann (CH) Malte Kelm (DE) Alexander Kharlamov (NL)* Helmut U. Klein (US) Juhani Knuuti (FI) Jon Kobashigawa (US) Richard Kobza (CH) Michel Komajda (FR) Michel Komajda (FR) Stavros V. Konstantinides (DE) Nicolle Kränkel (DE)

Steen Dalby Kristensen (DK) Henry Krum (UK) Carolyn S.P. Lam (US) Irene Lang (AT) Gaetano A. Lanza (IT) Ulrich Laufs (DE) Christophe Leclercq (FR) Adelino Leite-Moreira (PT) John Lekakis (GR) Pedro A. Lemos (BR) Amir Lerman (US) Eli I. Lev (IL) Eti I. Lev (IL) Peter Libby (US) Gregory Y.H. Lip (GB) Massimo Lombardi (IT) Russell V. Luepker (US) François Mach (CH) Winfried Maerz (DE) Aldo Pietro Maggioni (IT) Felix Mahfoud (DE) Eduardo Marban (US) Koon-Hou Mak (SG) V. Mareev (RU) Barry Maron (US) Gerald Maurer (AT) William McKenna (GB) Jawahar L. Mehta (US) Bernhard Meier (CH) Franz H. Messerli (US) Gilles Montalescot (FR) Christian Müller (CH) Toyoaki Murohara (JP) Franz-Josef Neumann (DE) Georg Nickenig (DE) José C. Nicolau (BR) Markku S. Nieminen (FI) Petros Nihoyannopoulos (UK) Steven E. Nissen (US) Uwe Nixdorff (DE) Uwe Nixdorff (DE) Suzanne Oparil (US) Yukio Ozaki (JP) Seung-Jung Park (KR) Terje R. Pedersen (NO) Joep Perk (SE) Eric Peterson (US) Marc A. Pfeffer (US) Eugenio Picano (IT) Jonathan P. Piccini (US) Fausto Jose Pinto (PT) Fausto Jose Pinto (PT) Bertram Pitt (US) Pjotr Ponikowski (PL) Ton Rabelink (NL) Frank Rademakers (BE) Daniel J. Rader (US) Shahbudin Rahimtoola (US) Kausik Ray (UK) Flavio Ribichini (IT) Paul M. Ridker (US) Walter Riesen (CH) Marco Roffi (CH) Raphael Rosenhek (AU)

Carlos E. Ruiz (US) Lars Rydén (SE) Julio Sandoval (MX) François Schiele (FR) Gerhard Schuler (DE) Heribert Schunkert (DE) Markus Schwaiger (DE) Peter J. Schwartz (IT) Christian Seiler (CH) Paul Sergeant (BE) Thomas Hellmut Schindler (CH) Ajay M. Shah (UK) Dipen Shah (CH) Evgeny Shlyakhto (RU) Maarten Simoons (NL) Karin Sipido (BE) Peter Sogaard (DK) Scott Solomon (US) Rudolf Speich (CH) Christodoulos Stefanadis (GR) Philippe Gabriel Steg (FR) Steven Steinhubl (CH) Gregg W. Stone (US) Isabella Sudano (CH)* Corrado Tamburino (IT) Luigi Tavazzi (IT) Michal Tendera (PL) Stefan Toggweiler (CH)* Gianni Tognoni (IT) Lale Tokgozoglu (TU) Adam Torbicki (PL) Dimitris Tousoulis (GR) Bernd van der Loo (CH) Dirk van Veldhuisen (The Netherlands) Panagiotis Vardas (GR) Albert Varga (HU) Agostino Virdis (IT) Renu Virmani (US) Jens-Uwe Voigt (BE) Massimo Volpe (IT) Nico Van de Veire (BE)* Ron van Domburg (NL)* Arnold Von Eckardstein (CH) Ron Waksman (US) Lars Wallentin (SE) Johannes Waltenberger (DE) Christian Weber (DE) Christian Weber (DE) Peter Wenaweser (CH) Harvey D. White (NZ) Petr Widimsky (CZ) James T. Willerson (US) Bryan Williams (GB) Stephan Windecker (CH) Kai Wollert (DE) Thihong Yang (CH) Zhihong Yang (CH) Seppo Ylä-Herttuala (FI) Cheuk-Man Yu (CN) José Luis Zamorano (ES) Andreas Michael Zeiher (DE)

*Elite Reviewers, The Editorial Team would like to thank these individuals for their outstanding contributions as reviewers for the European Heart Journal.